An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)

American Heart Journal

Volumn 169, Issue 4, 2015, Pages 472-478.e5

  Gibson, C Michael ^a   Mehran, Roxana ^b   Bode, Christoph ^c   Halperin, Johnathan ^b   Verheugt, Freek ^d   Wildgoose, Peter ^e   Van Eickels, Martin ^f   Lip, Gregory Y H ^g   Cohen, Marc ^h   Husted, Steen ⁱ   Peterson, Eric ^j   Fox, Keith ^k  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Jansen Pharmaceuticals Inc   (United States)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; CREATININE; DABIGATRAN; EPTIFIBATIDE; HEPARIN; HIRULOG; RIVAROXABAN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE; VITAMIN K GROUP;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; ELECTROCARDIOGRAPHY; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ATRIAL FIBRILLATION; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME; VITAMIN K;

EID: 84927573989     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.12.006     Document Type: Article

References (18)

1. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 18 2001 2370 2375
2. W.B. Kannel, and E.J. Benjamin Status of the epidemiology of atrial fibrillation Med Clin North Am 92 1 2008 17 40 [ix]
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 1991 983 988
4. H.J. Lin, P.A. Wolf, and M. Kelly-Hayes Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 10 1996 1760 1764
5. J.L. Anderson, J.L. Halperin, and N.M. Albert Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 18 2013 1935 1944
6. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 12 2007 857 867
7. M.C. Fang, Y. Chang, and E.M. Hylek Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation Ann Intern Med 141 10 2004 745 752
8. R. Tadros, and S. Shakib Warfarin-indications, risks and drug interactions Aust Fam Physician 39 7 2010 476 479
9. A. Rubboli, M. Colletta, and J. Valencia Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting J Interv Cardiol 22 4 2009 390 397
10. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 9526 2006 1903 1912
11. M.B. Leon, D.S. Baim, and J.J. Popma A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators N Engl J Med 339 23 1998 1665 1671
12. J.S. Paikin, D.S. Wright, M.A. Crowther, S.R. Mehta, and J.W. Eikelboom Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents Circulation 121 18 2010 2067 2070
13. W.J. Dewilde, T. Oirbans, and F.W. Verheugt Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 9872 2013 1107 1115
14. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Europace 12 10 2010 1360 1420
15. J.J. You, D.E. Singer, and P.A. Howard Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e531S e575S
16. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
17. J.L. Mega, E. Braunwald, and S. Mohanavelu Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 9683 2009 29 38
18. J.L. Mega, E. Braunwald, and S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 1 2012 9 19